Peregrine Pharmaceuticals Inc. (PPHM)

Oncology Corporate Profile

Stock Performance

4.0800
-0.0500

3 Month Stock History Chart

HQ Location

14282 Franklin Avenue
Tustin, CA 92780

Company Description

Peregrine Pharmaceuticals is a biopharmaceutical company focused on the research, development and commercialization of novel therapeutics for cancer and a wide range of viral diseases. Peregrine technologies target various physical structures unique to malignant or infected cells as a means to selectively target therapy and diagnostics, while sparing normal, healthy cells.

Website: http://www.peregrineinc.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
bavituximabanti-phospholipid monoclonal antibody2nd line metastatic Non Small Cell Lung Cancer (NSCLC)III
bavituximab (+ paclitaxel and carboplatin)anti-phospholipid monoclonal antibody1st line Breast cancerII
bavituximab (+ gemcitabine)anti-phospholipid monoclonal antibody1st line metastatic Pancreatic cancerII
bavituximab (+ gemcitabine)anti-phospholipid monoclonal antibody1st line metastatic Pancreatic cancerII
bavituximab (+ paclitaxel and carboplatin)anti-phospholipid monoclonal antibody1st line Non Small Cell Lung Cancer (NSCLC)II
bavituximab (+ docetaxel)anti-phospholipid monoclonal antibody2nd line Breast cancerII
bavituximab (+ docetaxel)anti-phospholipid monoclonal antibody2nd line Non Small Cell Lung Cancer (NSCLC)II
bavituximab (+ sorafenib)anti-phospholipid monoclonal antibodyHepatocellular carcinoma (HCC)II
bavituximab (+ durvalumab)anti-phospholipid monoclonal antibodyNon Small Cell Lung Cancer (NSCLC)IIAstraZeneca
Cotara®tumor necrosis therapy (TNT)2nd line metastatic Glioblastoma Multiforme (GBM)II
bavituximab (+ sorafenib)anti-phospholipid monoclonal antibody1st line metastatic Hepatocellular carcinoma (HCC)I
bavituximab (+ carboplatin and pemetrexed)anti-phospholipid monoclonal antibody1st line metastatic Non Small Cell Lung Cancer (NSCLC)I
bavituximab (+ pemetrexed and carboplatin)anti-phospholipid monoclonal antibody1st line metastatic non-squamous Non Small Cell Lung Cancer (NSCLC)I
bavituximab (+ capecitabine and radiation)anti-phospholipid monoclonal antibodyMetastatic rectal adenocarcinomaI
bavituximab(+ MEDI-4736)anti-PD-L1 therapyVarious cancer typesIAstraZeneca
124-PGN650radiolabeled PS-targeting monoclonal antibody fragmentVarious cancer typesI

View additional information on product candidates here »

Source: http://www.peregrineinc.com

Recent News Headlines

Preclinical Research Demonstrates Peregrine Pharmaceuticals' PS-Targeting Antibodies Enhance the Anti-Tumor Activity of PD-L1 Checkpoint Inhibitors in Model of Triple Negative Breast Cancer (TNBC)

10/24/2016 04:51 pm

(Peregrine Pharmaceuticals) Oct 24, 2016 - Peregrine Pharmaceuticals, Inc., a biopharmaceutical company committed to improving patient lives by manufacturing high quality products for biotechnology and pharmaceutical companies and advancing its proprietary R&D pipeline, today announced the presentation of preclinical study data demonstrating that phosphatidylserine (PS)-targeting antibodies similar to bavituximab are able to enhance the anti-tumor activity of anti-PD-L1 therapy in a model of triple negative breast cancer (TNBC).

Peregrine Licenses Novel Exosome-Based Cancer Detection and Monitoring Technology from UT Southwestern Medical Center

7/14/2016 03:58 pm

(Peregrine) July 14, 2016 - Peregrine Pharmaceuticals, Inc. today announced that the company has entered into an exclusive licensing agreement with University of Texas (UT) Southwestern Medical Center for a novel exosome technology that has potential application as a simple blood test to detect or monitor cancer.

Walgreens Shuts 40 Theranos Outlets After Ending Partnership

6/13/2016 12:02 pm

(Bloomberg) June 12, 2016 - Walgreens Boots Alliance Inc. said it has terminated its relationship with blood-testing startup Theranos Inc. and will close the company’s testing centers in its stores.

Peregrine Pharmaceuticals Provides Corporate Update Highlighting Latest Developments for Contract Manufacturing and Drug Development Businesses

6/2/2016 05:25 pm

(NASDAQ) June 2, 2016 - Drug development strategy to focus on early stage clinical trials of bavituximab and immuno-oncology (I-O) combinations.

Pathologists Often Disagree on Biopsy Findings

3/30/2016 11:04 am

(Medscape Medical News) Mar 30, 2016 - Pathologists largely agree with each other when identifying invasive breast cancer on breast biopsy slides, but agreement is much lower when those slides suggest atypia or ductal carcinoma in situ (DCIS), according to a recent study.

Peregrine Pharmaceuticals Provides Update on Phase III SUNRISE Trial of Bavituximab

2/26/2016 12:58 pm

(Yahoo! Finance) Feb 25, 2016 - Peregrine Pharmaceuticals, Inc., a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that it is discontinuing the company’s Phase III SUNRISE trial of bavituximab in patients with previously treated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).

U.S. Food and Drug Administration (FDA) Grants Breakthrough Therapy Designation to Immunomedics for Sacituzumab Govitecan for the Treatment of Patients With Triple-Negative Breast Cancer

2/5/2016 12:00 pm

(NASDAQ) Feb 5, 2016 - Immunomedics, Inc., today announced that its lead investigational antibody-drug conjugate, sacituzumab govitecan, or IMMU-132, has received Breakthrough Therapy Designation from the FDA for the treatment of patients with triple-negative breast cancer (TNBC) who have failed at least 2 prior therapies for metastatic disease.

OSE Pharma Announces U.S. Initiation of Atalante 1, the Company's Global, Pivotal Phase 3 Trial for Tedopi Immunotherapy in Non-Small Cell Lung Cancer

2/5/2016 11:03 am

(Yahoo! Finance) Feb 4, 2016 - OSE Pharma SA, an immuno-oncology company developing a T-specific immunotherapy for late-stage cancer patients, today announced initiation in the United States of its Phase 3 clinical trial, Atalante 1. This global, pivotal trial will evaluate Tedopi®, the company's lead product, for advanced non-small cell lung cancer (NSCLC).

NIH Researchers Identify Striking Genomic Signature Shared By Five Types Of Cancer

2/5/2016 11:02 am

(NIH) Feb 5, 2015 - National Institutes of Health researchers have identified a striking signature in tumor DNA that occurs in five different types of cancer. They also found evidence that this methylation signature may be present in many more types of cancer.

Peregrine Pharmaceuticals Provides Update on Planned Expansion of Bavituximab Clinical Program in Lung, Breast and Other Cancers

1/11/2016 05:12 pm

(Yahoo! Finance) Jan 11, 2016 - Phase II study in NSCLC in collaboration with AstraZeneca evaluating bavituximab plus durvalumab to expand lung cancer program in Q1 2016; Phase II/III study in HER2-negative metastatic breast cancer is now underway with a second phase II study in early stage triple negative breast cancer to begin in Q1 2016.

NCCN Awarded $2 Million in Research Funding from Peregrine Pharmaceuticals to Study Bavituximab in Various Cancers

1/6/2016 05:31 pm

(NCCN) Jan 6, 2016 - The NCCN Oncology Research Program (ORP) was awarded a $2-million grant from Peregrine Pharmaceuticals, Inc. to facilitate studies of bavituximab in various cancers.

AstraZeneca and Peregrine Pharmaceuticals Expand Ongoing Immuno-Oncology Collaboration to Include Phase II Lung Cancer Combination Clinical Trial

10/15/2015 05:33 pm

(MarketWatch) Oct 15, 2015 - Peregrine Pharmaceuticals, Inc., a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that it has expanded its ongoing cancer immunotherapy clinical collaboration with AstraZeneca to include a second, later-stage trial.

What Race Has to Do With Breast Cancer

10/13/2015 11:04 am

(TIME) Oct 12, 2015 - Researchers provide the most detailed look yet at why minority women tend to fare worse with breast cancer.

Rare Childhood Leukemia Reveals Surprising Genetic Secrets

10/13/2015 11:04 am

(UCSF) Oct 12, 2015 - A coalition of leukemia researchers led by scientists from UC San Francisco has discovered surprising genetic diversity in juvenile myelomonocytic leukemia (JMML), a rare but aggressive childhood blood cancer.

Is This Cancer Treatment Worth It? New Tool Offers Patients Data

10/13/2015 11:03 am

(Bloomberg) Oct 13, 2015 - For the first time, a consortium of top U.S. cancer hospitals will provide patients with guidance about the cost of drugs used in their treatment, helping address a concern for many people undergoing a major medical event -- what the financial repercussions of their condition are.

Exclusive - Transatlantic Divide: How U.S. Pays Three Times More For Drugs

10/12/2015 12:02 pm

(Reuters) Oct 12, 2015 - U.S. prices for the world's 20 top-selling medicines are, on average, three times higher than in Britain, according to an analysis carried out for Reuters.

Rosetta Genomics Launches BRAF Mutation Assay

10/12/2015 11:05 am

(MarketWatch) Oct 12, 2015 - Rosetta Genomics Ltd., a leading developer and provider of microRNA-based and other molecular diagnostics, announces the launch of a molecular test for BRAF mutation analysis to help personalize therapy for melanoma and colon cancer patients. This newest assay will complement its broad offerings so that oncologists can optimize treatment decisions for their cancer patients.

Roche Wins the First HPV Primary Screening Tender in Europe

10/12/2015 11:05 am

(Roche) Oct 12, 2015 - Roche announced today that it has been awarded a 5-year contract by the National Institute for Public Health and the Environment (RIVM) in the Netherlands for implementation of the cobas® HPV Test as the first-line, primary screening test in the national cervical cancer screening program.

Stand Up To Cancer Makes $7.5 Million in Cancer Research Funding Available to Early-career Scientists

10/12/2015 11:05 am

(AACR) Oct 9, 2015 - Stand Up To Cancer (SU2C) is making $7.5 million in research funding available to early-career scientists who are pursuing innovative approaches to cancer, the American Association for Cancer Research (AACR) announced today. A total of 10 Innovative Research Grants (IRGs) will be funded up to $750,000 each over three years.

UK Charity Unveils £100M Cancer Grants Scheme

10/12/2015 11:05 am

(PharmaTimes [UK]) Oct 12, 2015 - Cancer Research UK has this morning launched its mammoth Grand Challenges cancer grants scheme, which will offer up an overall investment of £100 million to help overcome the greatest barriers to beating the disease.

Novartis to Invest Further $15M in Gamida Cell

10/12/2015 11:04 am

(Globes [Israel]) Oct 10, 2015 - Multinational pharmaceutical giant Novartis International AG has announced that it is investing up to an additional $15 million in Israeli stem cell company Gamida Cell.

To Die At Home, It Helps To Have Someone Who Can Take Time Off Work

10/12/2015 11:04 am

(NPR/Shots blog) Oct 9, 2015 - A wide base of support is needed in order for a patient's wish to die at home to be made real — including, in some cases, whether someone can take time off work to be with their loved one in their final days, a study finds.

Bigger Challenges For Rural Cancer Patients

10/12/2015 11:04 am

(The Gazette [Cedar Rapids, IA]) Oct 11, 2015 - Rural Americans fighting cancer face even more challenges than those who live in more urban areas, including a lack of nearby physicians and treatment, transportation issues, and access to cancer screenings and follow-up care.

Eli Lilly's Good Cholesterol Drug Went Bad. Here's What That Means For Pharma

10/12/2015 11:03 am

(Forbes) Oct 12, 2015 - This morning, Eli Lilly announced that evacetrapib, its experimental drug to raise good cholesterol, failed to prevent patients from getting heart attacks and strokes in a large clinical trial.

Value-Based Payments: But Is There Any Value for Doctors?

10/12/2015 11:03 am

(Medscape Business of Medicine) Oct 8, 2015 - The health system is moving toward value-based medicine, a care-management strategy that pays doctors for pursuing high quality while simultaneously reducing costs.

Merck KGaA Bets On Cancer Drugs To Revitalize German Firm

10/12/2015 11:03 am

(Reuters) Oct 12, 2015 - Merck KGaA is betting on its oncology pipeline to revitalize the German drugmaker as it sees falling sales from its best-selling medicine, multiple sclerosis treatment Rebif.

FDA Expands Use of Nivolumab in Lung Cancer

10/12/2015 11:01 am

(Medscape Medical News) Oct 9, 2015 - The US Food and Drug Administration (FDA) today expanded the approved use of nivolumab (Opdivo, Bristol-Myers Squibb) to include the treatment of patients with metastatic nonsquamous, non-small-cell lung cancer (NSCLC) whose disease progressed during or after platinum-based chemotherapy.

AstraZeneca and Peregrine Pharmaceuticals to Collaborate on Immuno-Oncology Combination Clinical Trial

8/24/2015 04:21 pm

(AstraZeneca) Aug 24, 2015 - Collaboration to focus on cancer immunotherapy combination of Peregrine’s ps-targeting bavituximab and AstraZeneca’s PD-L1 Inhibitor MEDI4736.

Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform

7/8/2015 11:04 am

(MarketWatch) July 8, 2015 - Trovagene, Inc., a developer of cell-free molecular diagnostics, today announced the launch of a study that aims to determine utility of the Company's Precision Cancer Monitoring (PCM) technology for predicting response to treatment in advanced melanoma patients receiving one or a combination of the novel immunotherapy agents Yervoy® (ipilumumab), a CTLA-4 inhibitor, and Opdivo® (nivolumab), a PD-1 inhibitor.

Peregrine Pharmaceuticals Enters Into Research Collaboration to Investigate Novel PS-Targeting Immunotherapy Combinations

5/29/2015 08:07 pm

(NASDAQ) May 29, 2015 - Peregrine Pharmaceuticals, Inc., a biopharmaceutical company focused on advancing bavituximab, a novel immuno-oncology agent in Phase III development for the treatment of lung cancer, today announced that the company has entered into a sponsored research agreement with Memorial Sloan Kettering Cancer Center (MSK) to explore the potential of Peregrine's proprietary phosphatidylserine (PS)-targeting antibody platform.

GenSpera Expands Phase II Glioblastoma Trial of Mipsagargin

5/13/2015 11:05 am

(GenSpera) May 13, 2015 - GenSpera, Inc. announced today the successful completion of the first stage of an ongoing Phase II study of its lead investigational agent, mipsagargin (G-202), in glioblastoma (brain cancer) and the continuation of enrollment for an expansion phase of the trial.

Medica and Minnesota Oncology Collaborate to Improve Patient Support Services

3/26/2015 12:03 pm

(The US Oncology Network) Mar 26, 2015 - Minnesota Oncology, the premier cancer physician group throughout the Twin Cities and an affiliate of The US Oncology Network, today announced that as of January 1, 2015, select Medica members have access to a comprehensive cancer care management program.

World's Most Popular Weed-killer Labeled 'Probable Carcinogen'

3/23/2015 12:00 pm

(Chicago Tribune/Associated Press) Mar 23, 2015 - One of the world's most popular weed-killers — and the most widely used kind in the U.S. — has been labeled a probable carcinogen by the International Agency for Research on Cancer.

Phase II Clinical Data of Peregrine Pharmaceuticals' Bavituximab in Combination With Sorafenib Presented at ASCO Gastrointestinal Cancers Symposium

1/16/2015 04:59 pm

(Yahoo! Finance) Jan 16, 2015 - Peregrine Pharmaceuticals, Inc. today announced the presentation of clinical data related to the company's immuno-oncology development program and its lead investigational immunotherapy drug candidate bavituximab at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium.

ERYTECH Reports Additional Positive Phase III Results From Clinical Study With ERY-ASP/GRASPA® in Acute Lymphoblastic Leukemia

12/8/2014 05:01 pm

(CNBC) Dec 8, 1014 - ERYTECH reports additional positive Phase III results from the pivotal study with ERY-ASP/GRASPA® in Acute Lymphoblastic Leukemia.